An announcement from Fate Therapeutics (FATE) is now available.
Edward J. Dulac III has announced his resignation as Chief Financial Officer of Fate Therapeutics, Inc., effective June 14, 2024, to pursue new opportunities. The company’s board plans to reinstate President and CEO J. Scott Wolchko as CFO, a role he previously held until August 2020, immediately following Dulac’s departure. Wolchko’s background is detailed in the company’s recent proxy statement.
Find detailed analytics on FATE stock on TipRanks’ Stock Analysis page.
